Stocks Eli Lilly and Co


  • *Zoetis, Pfizer assets could attract Bayer in future. Possible targets for the German company could include veterinary drug firm Zoetis and Pfizer's consumer health business, the two sources said. Bayer, Zoetis and Pfizer declined to comment.

  • Early movers: GIS, ACN, WGO, FDX, LL, VRX & more Thursday, 17 Dec 2015 | 7:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Global markets soar after Fed rate hike Thursday, 17 Dec 2015 | 7:45 AM ET

    A post-Fed stock rally this morning, following the central banks first interest rate increase in more than nine years.

  • Dec 16- The U.S. Food and Drug Administration on Wednesday approved Eli Lilly& Co's diabetes drug Basaglar, a cheaper version of Sanofi AG's top-selling drug Lantus. In September Lilly entered a settlement agreement to resolve patent litigation with Sanofi over Basaglar, allowing Lilly and its partner, Boehringer Ingelheim, to launch Basaglar in the United...

  • *Sanofi in talks to acquire Boehringer consumer health. *Boehringer to buy Sanofi's animal health arm Merial. PARIS/ LONDON, Dec 15- Sanofi and Boehringer Ingelheim are in exclusive talks over a $20 billion swap of the French pharmaceuticals company's animal health business for the family-owned German group's consumer health operation.

  • It was not clear from the FDA report which antibiotics were used on various animals, why and in what volume. The FDA in 2013 released voluntary guidelines for drug makers and agricultural companies to phase out antibiotic use as a growth enhancer in livestock. "Sales does not equal use and use is not the same thing as resistance," said Ron Phillips, spokesman for the...

  • Dec 4- Eli Lilly& Co said on Friday it scrapped development of an experimental diabetes treatment that had raised concerns of liver problems. Nearly 12 in 1000 Americans are diagnosed with diabetes every year, according to the Centers for Disease Control and Prevention. Eli Lilly's shares closed at $83.06 on Thursday.

  • Lilly stops development of diabetes treatment Friday, 4 Dec 2015 | 8:14 AM ET

    Dec 4- Eli Lilly& Co said it stopped developing its experimental diabetes treatment after discussions with regulatory authorities and external experts.

  • Traders talk Barclays' bullish pharma call Tuesday, 1 Dec 2015 | 1:54 PM ET

    The "Halftime Report" traders give their top trades of the show.

  • UPDATE 1-FDA approves Lilly's lung cancer drug Tuesday, 24 Nov 2015 | 1:07 PM ET

    Nov 24- The U.S. Food and Drug Administration said it had approved Eli Lilly& Co's Portrazza, in combination with two forms of chemotherapy, to treat patients with a type of lung cancer. The FDA's approval on Tuesday comes about four months after an advisory panel to the agency recommended the drug be cleared for sale along with the warnings. Eli Lilly's shares were...

  • FDA approves Lilly's lung cancer drug Tuesday, 24 Nov 2015 | 12:01 PM ET

    Nov 24- The U.S. Food and Drug Administration on Tuesday approved Eli Lilly& Co's cancer treatment, Portrazza, in combination with two forms of chemotherapy to treat patients with advanced squamous non-small cell lung cancer.

  • Cramer: Most amazing transformation I've ever seen Friday, 20 Nov 2015 | 6:57 PM ET

    Jim Cramer says this week was the most amazing transformation he has ever seen before. But can the bull continue to dance?

  • LONDON, Nov 18- Pearson boss John Fallon faces a daunting task to arrest the decline of the world's biggest education publisher as it battles growing political and economic strife. Fallon has endured a rough ride since he took over in 2013, with a string of profit warnings marking his tenure, in an abrupt end to the steady growth enjoyed by his predecessor...

  • NEW YORK, Nov 17- Healthcare companies that can either contain costs or develop medications to treat rare diseases, known as orphan drugs, will be the most likely to outperform in the coming year, said John Fraunces, whose Turner Medical Sciences Long/Short fund is among the top performing healthcare funds over the last 5 years. He is shorting AbbVie Inc, for...

  • A deadly disease on track to bankrupt Medicare Tuesday, 10 Nov 2015 | 10:00 AM ET
    Alzheimer's victim

    About 1 in 5 Medicare dollars is spent on this disease that affects over 5 million Americans. Yet not enough is being done to find a cure.

  • The American Heart Association is holding its annual scientific sessions in Orlando, Florida from Nov 7 to 11, at which the latest clinical trials and research in heart care are being presented for thousands of cardiologists and researchers, including a large government-sponsored study on the benefits of more intensive blood pressure lowering in patients...

  • ORLANDO, Nov 9- Eli Lilly's new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday. The 3- year trial of more than 7,000 patients caused a sensation in September,...

  • One of their favorite targets is Pasadena, California- based Alexandria Real Estate Equities Inc, which owns the largest collection of high-end lab space in such research clusters as San Diego, San Francisco and Cambridge, Massachusetts. That has helped push rents for lab spaces up by 7.4 percent over the last year in Boston, the nation's most expensive market...

  • LONDON, Oct 27- A cheap off-patent drug that relieves some symptoms of Alzheimer's disease may also help keep people at an advanced stage of the illness out of nursing homes, at least for a while. Donepezil, originally sold by Eisai and Pfizer as Aricept and now available generically for just over 20 pounds a year, works by raising the levels of chemicals within the...

  • Dow futures up 100 points amid Draghi remarks, data Thursday, 22 Oct 2015 | 9:24 AM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stock index futures pointed to a sharply higher open on Thursday.